A potential solution for eliminating hypoxia as a cause for radioresistance

Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism

(2018) Martin Benej et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hypoxia-activated prodrugs: paths forward in the era of personalised medicine

(2016) Francis W Hunter et al.   BRITISH JOURNAL OF CANCER

Baseline Tumor Oxygen Saturation Correlates with a Pathologic Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

(2012) S. Ueda et al.   CANCER RESEARCH

Is there a role for tirapazamine in the treatment of cervical cancer?

(2012) Prafull Ghatage et al.   Expert Opinion on Drug Metabolism & Toxicology

Imaging hypoxia to improve radiotherapy outcome

(2012) Michael R. Horsman et al.   Nature Reviews Clinical Oncology

The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia

(2011) J. Wang et al.   CLINICAL CANCER RESEARCH

Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – A systematic review and meta-analysis

(2011) Jens Overgaard   RADIOTHERAPY AND ONCOLOGY

Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group

(2010) Danny Rischin et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative Optical Spectroscopy: A Robust Tool for Direct Measurement of Breast Cancer Vascular Oxygenation and Total Hemoglobin Content In vivo

(2009) J. Q. Brown et al.   CANCER RESEARCH